Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NEXZd2FCeG:ydH;zbZMhSXO|YYm= NFrZNo8y6oDVNdMg{txO NYnzRW5DPDhiaB?= M1PKT4lvcGmkaYTzJINmdGxiZ4Lve5Rp MXOyOlMzQTZyOB?=
PLC/PRF/5  NInZTlFCeG:ydH;zbZMhSXO|YYm= MYix5qCUPcLizszN NU[yRmNqPDhiaB?= NGDYW|JqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M{T5eFI3OzJ7NkC4
HepG2  MUDBdI9xfG:|aYOgRZN{[Xl? MojvNgKBmzYEoN88US=> NH\Tfng1QCCq M{LVXIlvcGmkaYTzJINmdGxiZ4Lve5Rp MVeyOlMzQTZyOB?=
HEK293 MWPGeY5kfGmxbjDBd5NigQ>? MVWwMlXjiIoQvF2= NUO3S5d3Oi92L{[gbC=> M3juSJJm\HWlZYOgS3JRPzhiZYjwdoV{e2mxbh?= MoLzNlU5PThyM{K=
GEO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPGNE4xOS1{MDFOwG0> MnjUPVYhcA>? M2TLZWROW09? NWrEcol2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIXDVWkzPTh|OEO5NS=>
SW48 NWfQcFNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\QdGsxNjBzLUKwJO69VQ>? Mn;JPVYhcA>? NFW0fI1FVVOR NYDGSXFKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEn3R3UzPTh|OEO5NS=>
HT29 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S0e|AvODFvMkCg{txO MUS5OkBp NHjDOmtFVVOR Mm\RbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{j3[|I2QDN6M{mx
SW480 NIDBV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxVVAvODFvMkCg{txO MnHHPVYhcA>? NIGxd2lFVVOR MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXPyXlZJOjV6M{izPVE>
SW620 NG\jfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;wNE4xOS1{MDFOwG0> M4myNVk3KGh? NH\L[oFFVVOR MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3W0TVI2QDN6M{mx
HCT116 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzVNE4xOS1{MDFOwG0> MUC5OkBp MXrEUXNQ NV7qS4prcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnfqNlU5Ozh|OUG=
LOVO M3H1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi3UVkxNjBzLUKwJO69VQ>? M4Hxdlk3KGh? MnXCSG1UVw>? NUe5Tmk4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2DUS|I2QDN6M{mx
HCT150 M1T3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PwcVAvODFvMkCg{txO M3W1dlk3KGh? M32yeWROW09? NHuxSo5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlPONlU5Ozh|OUG=
SW48-CR MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrKdIptOC5yMT2yNEDPxE1? MljPPVYhcA>? MVzEUXNQ NG\ROpFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4j3ZVI2QDN6M{mx
GEO-CR M3LIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILtOFcxNjBzLUKwJO69VQ>? M{jrdlk3KGh? MYTEUXNQ MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1;mU|I2QDN6M{mx
KB-31 NVjmRVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXQTWM2OD13LkZCtVAvOyCwTR?= M3H4RVI2PzV|M{[x
KB-G2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTlwMdMxNE4yKG6P MXGyOVc2OzN4MR?=
LLC-PK1 NIHoPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDhTWM2OD12Mj6wxtE{NjJibl2= NILF[XczPTd3M{O2NS=>
LLC-PK1/MRP2 NF:0N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PDSmlEPTB;OEKuOOKyOi55IH7N MmnoNlU4PTN|NkG=
HEK293 M{DwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLmU|U{UUN3ME2xNU4xyrFzLkKgcm0> MofsNlU4PTN|NkG=
HEK293/OATP1B1 NFn4U2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjoTWM2OD14LkNCtVAvOyCwTR?= M2jYeVI2PzV|M{[x
HROC18 M2DGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XOVmlEPTB;MT6zJO69VQ>? M1P6NFI2OzB7OUG0
HROC24 M{ewPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwNjFOwG0> M1TofFI2OzB7OUG0
HROC43 NXrjTpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvLcVBmUUN3ME21MlMh|ryP M4nNd|I2OzB7OUG0
HROC46 M1;6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnBOoxFUUN3ME2yMlQh|ryP MWGyOVMxQTlzNB?=
RJ345 MX3GeY5kfGmxbjDBd5NigQ>? NES2foIxNjVxNTFOwG0> M2nhcVI1KGh? NYi0O5FxTE2VTx?= NVXtV5dzcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v M4HaNVI2OjV|OUm0
RJ348 NHTjPHhHfW6ldHnvckBCe3OjeR?= MWiwMlUwPSEQvF2= NWPVblBMOjRiaB?= MkS3SG1UVw>? MY\pcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= MY[yOVI2Ozl7NB?=
MCF-7 NUjhfW9WTnWwY4Tpc44hSXO|YYm= NIr3WJAxNjVxNTFOwG0> M{TRT|I1KGh? NGm5OpZFVVOR NIjYS2tqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> MlHPNlUzPTN7OUS=
MDA-MB-231 MVjGeY5kfGmxbjDBd5NigQ>? NULNWlJwOC53L{Wg{txO MUKyOEBp NILs[pFFVVOR NInxbmpqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NXrobIxMOjV{NUO5PVQ>
HT15 M2[wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnTWYJbOS1{MDFOwG0> MUm0PEBp NITHXnpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MojTNlUxPzFyMUi=
DLD1 NGGyNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Ze4Z2OS1{MDFOwG0> NGrHVVA1QCCq Mom5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoXkNlUxPzFyMUi=
HT-29 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW4e24yNTJyIN88US=> NWjQdGNSPDhiaB?= MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmD6NlUxPzFyMUi=
Hct-116 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL1d3gyNTJyIN88US=> NIDSUHo1QCCq M3XQOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYGyOVA4OTBzOB?=
HT15 M3nJSmFxd3C2b4Ppd{BCe3OjeR?= MmHaNU0yOCEQvF2= NYHKb3lHPDhiaB?= MUjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWnzSIpYOjVyN{GwNVg>
DLD1 MX;BdI9xfG:|aYOgRZN{[Xl? M2HOXlEuOTBizszN NFTYfoY1QCCq MVrpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NG[zbIQzPTB5MUCxPC=>
HT-29 MkC2RZBweHSxc3nzJGF{e2G7 M{XmSlEuOTBizszN MkHOOFghcA>? Mkf2bY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Moq2NlUxPzFyMUi=
Hct-116 M3\xW2Fxd3C2b4Ppd{BCe3OjeR?= MYqxMVExKM7:TR?= NXX1O5Y1PDhiaB?= M1vac4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUSyOVA4OTBzOB?=
GBM5 M2rS[mFxd3C2b4Ppd{BCe3OjeR?= NYjTXZhbOC534pETNU4x6oDLzszN NXPE[Zh2OjRiaB?= NIfkcnlFVVOR NXjBSGFRcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp NVPtTHR{OjR7MUGyNVU>
GBM6 NXfiVZYzSXCxcITvd4l{KEG|c3H5 M{fnOVAvPeLCk{GuNQKBkc7:TR?= M1XE[FI1KGh? MWTEUXNQ NV\sZXo1cW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp M2PFUVI1QTFzMkG1
GBM12 MUHBdI9xfG:|aYOgRZN{[Xl? NVHZc4d4OC534pETNU4x6oDLzszN M{ixclI1KGh? M1PQdGROW09? M37D[YlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> Mle2NlQ6OTF{MUW=
GBM14  M{\oW2Fxd3C2b4Ppd{BCe3OjeR?= NIjVe|ExNjYkgKOxMlDjiIoQvF2= NEW5VHczPCCq NIH6UHVFVVOR M2jIc4lvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> MnvYNlQ6OTF{MUW=
Hep3B MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj4NgKBmzJwNdMg{txO MWqyOE81QC95MjDo M4LRe4lvcGmkaYTzJINmdGxiZ4Lve5Rp NXf3fpFROjR6OEW4PVA>
PLC/PRF/5  NE\RbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7yNgKBmzJwNdMg{txO MXmyOE81QC95MjDo MnK4bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NGP5NlIzPDh6NUi5NC=>
HepG2  M4P1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX1XWhTOeLCk{KuOeKh|ryP MVSyOE81QC95MjDo NVPFXGszcW6qaXLpeJMh[2WubDDndo94fGh? MorNNlQ5QDV6OUC=
HCT116  NWXZXoxETnWwY4Tpc44hSXO|YYm= NFTCeXoyOC9{MD:0NEDPxE1? NU\O[G0zOjRiaB?= NWTQbo1IcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJI1TVkFiZYjwdoV{e2mxbjDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NVTPZ2pMOjR5NkO2NVE>
Lim2405 MmToSpVv[3Srb36gRZN{[Xl? NXvaeZRsPDBizszN NIq4Uo0zPCCq MYXpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NWnWcIl7OjR5NkO2NVE>
LoVo MkPaSpVv[3Srb36gRZN{[Xl? NH;kfoo1OCEQvF2= NFrtWpQzPCCq NYDXOplwcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| M4rIUVI1PzZ|NkGx
Lim1215 Ml7aSpVv[3Srb36gRZN{[Xl? NFzwOnQ1OCEQvF2= MlXjNlQhcA>? Mk\FbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M3ezRVI1PzZ|NkGx
SW48 M4HVbWZ2dmO2aX;uJGF{e2G7 MYG0NEDPxE1? NHLrTXozPCCq M1juS4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NFrDVJMzPDd4M{[xNS=>
RKO  NGX5UWZHfW6ldHnvckBCe3OjeR?= M4S5N|QxKM7:TR?= Mo[2NlQhcA>? NGHRSJRqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MnHKNlQ4PjN4MUG=
SW837 MmDYSpVv[3Srb36gRZN{[Xl? MYC0NEDPxE1? M17aTlI1KGh? MmHnbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M2XQeFI1PzZ|NkGx
SW1463 MofOSpVv[3Srb36gRZN{[Xl? NEDvbnU1OCEQvF2= MoPSNlQhcA>? MWjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> Mk\BNlQ4PjN4MUG=
SW480 M4HhW2Z2dmO2aX;uJGF{e2G7 M1jMRVQxKM7:TR?= NEW1O20zPCCq NGSzTpBqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NVPZb4x3OjR5NkO2NVE>
Vaco432 NVqz[JQ{TnWwY4Tpc44hSXO|YYm= NX7hVoVwPDBizszN M{[zclI1KGh? MlzrbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NGPwSJozPDd4M{[xNS=>
Vaco400 MoDhSpVv[3Srb36gRZN{[Xl? MkLJOFAh|ryP MUSyOEBp M4\ZZolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? Ml[1NlQ4PjN4MUG=
DLD1 Ml\KSpVv[3Srb36gRZN{[Xl? M1\6U|QxKM7:TR?= MmLMNlQhcA>? NX[wWGpvcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NHG4VJYzPDd4M{[xNS=>
HT29  NFHxZoVHfW6ldHnvckBCe3OjeR?= NED6dFc1OCEQvF2= NVTXbVdpOjRiaB?= NI\tfIVqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NWTlN21rOjR5NkO2NVE>
PLC/PRF/5  NELrNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zNgKBmzYEtV2= NYLGNFlYOjRxNEivO|IhcA>? NFL0SoRqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M{fSSVI{OTZ7MUS4
HepG2 NFzJWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOx5qCUPcL3TR?= M1TMNlI1NzR6L{eyJIg> M3rYS4lvcGmkaYTzJINmdGxiZ4Lve5Rp M4PnUlI{OTZ7MUS4
Hep3B  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjhO2p3OeLCk{ZCuW0> NX\rdJFVOjRxNEivO|IhcA>? MU\pcohq[mm2czDj[YxtKGe{b4f0bC=> Mn\tNlMyPjlzNEi=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID